piwil2 Antibody

What is PIWIL2 and why is it important in research?

PIWIL2 (piwi like RNA-mediated gene silencing 2) is a protein encoded by the PIWIL2 gene in humans. It plays crucial roles in RNA-mediated gene silencing and is also known by several alternative names including Mili, CT80, HILI, PIWIL1L, piwi-like protein 2, and 80kDa PIWIL2 short isoform. The full-length protein is approximately 109.8 kilodaltons in mass . PIWIL2 has gained significant research interest due to its involvement in cancer development and progression, making it a potential biomarker and therapeutic target. Understanding PIWIL2 function requires specific antibodies that can recognize the protein and its variants in various experimental contexts.

What PIWIL2 isoforms exist and how do they differ?

Research has identified several PIWIL2-like (PL2L) proteins beyond the full-length 110 kDa PIWIL2. These include PL2L80 (approximately 80 kDa), PL2L60 (approximately 60 kDa), PL2L50 (approximately 50 kDa), and PL2L40 (approximately 40 kDa) . These variants differ in their molecular weight, expression patterns, and potentially their functions. For instance, PL2L60 is predominantly expressed in tumor cell lines while the full-length PIWIL2 is more abundant in testicular tissues . These isoforms appear to result from alternative splicing or use of different promoters, as demonstrated by genomic and expression mapping (GEM) RT-PCR analysis showing variable expression of different exon regions across samples .

What types of PIWIL2 antibodies are available and how do they differ in specificity?

Multiple types of PIWIL2 antibodies are available, with varying specificities:

Polyclonal antibodies typically recognize multiple epitopes across the protein, while monoclonal antibodies target specific epitopes, allowing for greater precision in distinguishing between isoforms . Some antibodies are designed against peptide sequences shared between PIWIL2 and its variants, while others target unique regions specific to particular forms.

How should researchers validate the specificity of PIWIL2 antibodies?

Validating PIWIL2 antibody specificity requires a multi-faceted approach:

• Peptide competition assays: Preincubate the antibody with the immunizing peptide before application. Specific binding will be blocked, as demonstrated with human tumor cell lysates where 110 kDa, 80 kDa, 60 kDa, and 50 kDa protein bands were almost completely blocked by Piwil2 peptides .

• Knockout/knockdown controls: Use tissue or cells from PIWIL2 knockout models (such as mili−/− mice) as negative controls. Note that in such models, some PL2L variants may still be expressed if the knockout strategy doesn't affect all exons. For example, in mili−/− mice, only the full-length Piwil2 was completely disrupted while PL2L80 and PL2L60 proteins were still detectable at reduced levels .

• Cross-reactivity testing: Test antibodies against related proteins to ensure they don't cross-react with other PIWI family members.

• Multiple antibody comparison: Use different antibodies targeting distinct epitopes (such as Kao1 vs. Kao2/Kao3) and compare the detection patterns .

What is the optimal protocol for Western Blot detection of PIWIL2 and its variants?

For optimal Western blot detection of PIWIL2 and its variants:

• Sample preparation: Use appropriate lysis buffers that preserve protein integrity. For testicular tissue or cancer cell lines, standard RIPA buffer supplemented with protease inhibitors works effectively .

• Gel selection: Use gradient gels (4-12%) to effectively separate proteins ranging from 40-110 kDa.

• Antibody selection and dilution:

  • For detection of all variants: Use polyclonal antibodies (e.g., Piwil2-peptide specific pAb) at 2-4 μg/mL .

  • For specific detection of full-length PIWIL2: Use mAb Kao1 .

  • For detection of both PIWIL2 and PL2L proteins: Use mAbs Kao2 or Kao3 .

• Controls: Include positive controls (testicular tissue for full-length Piwil2; cancer cell lines for PL2L60) and negative controls (mili−/− mice tissues or peptide-blocked antibody reactions) .

• Signal development: Use enhanced chemiluminescence for sensitive detection, with exposure times optimized for each antibody and protein variant.

What are the key considerations for immunohistochemical detection of PIWIL2 in tissue samples?

When performing immunohistochemistry (IHC) for PIWIL2:

• Fixation and antigen retrieval: Optimize fixation conditions and antigen retrieval methods, as PIWIL2 epitopes may be sensitive to overfixation. Heat-induced epitope retrieval in citrate buffer (pH 6.0) is commonly effective.

• Antibody selection: Choose antibodies validated for IHC. Many commercial PIWIL2 antibodies are specifically tested for IHC applications .

• Differential expression patterns: Be aware that different isoforms may have distinct subcellular localizations and tissue distributions. For example, PL2L60 is predominantly expressed in cancer tissues while full-length PIWIL2 is more abundant in testicular tissues .

• Controls: Include positive controls (testicular tissue for full-length PIWIL2; cancer tissues for PL2L proteins) and negative controls (antibody diluent only, or isotype controls).

• Quantification: Establish clear scoring criteria for positivity, intensity, and subcellular localization to ensure reproducible results.

How can researchers distinguish between PIWIL2 isoforms in experimental systems?

Distinguishing between PIWIL2 isoforms requires strategic approaches:

• Isoform-specific antibodies: Use antibodies like mAb Kao1 that specifically recognize full-length PIWIL2 (~110 kDa) but not PL2L proteins, versus broader antibodies like Kao2 and Kao3 that detect multiple forms .

• Molecular weight analysis: Perform careful molecular weight analysis on Western blots, as each isoform has a characteristic size (110 kDa for full-length PIWIL2, 80 kDa for PL2L80, 60 kDa for PL2L60, etc.) .

• Exon-specific PCR: Implement GEM RT-PCR using primer pairs spanning different exon regions of PIWIL2. For example, primers covering exons 1-7, 6-14, 13-21, and 21-23 can help identify which transcripts are expressed . Cancer stem cell lines may show absence of exons 1-7 amplification while expressing other regions .

• Expression patterns: Leverage differential expression patterns – for example, PL2L60 is predominantly expressed in cancer cell lines while full-length PIWIL2 is more abundant in testicular tissues .

What analytical challenges exist when interpreting PIWIL2 antibody experimental results?

Several analytical challenges can complicate interpretation of PIWIL2 antibody results:

• Antibody cross-reactivity: Many antibodies recognize epitopes shared between PIWIL2 and PL2L proteins, leading to detection of multiple bands that must be carefully distinguished by molecular weight .

• Incomplete knockout models: In mili−/− mice, while full-length Piwil2 is disrupted, some PL2L proteins remain detectable at reduced levels due to alternative promoters or incomplete disruption of all exons . This can complicate the use of such models as negative controls.

• Variable expression levels: Different isoforms may be expressed at substantially different levels in the same tissue, requiring optimization of exposure times and antibody concentrations for detection .

• Cellular context dependency: Expression patterns of PIWIL2 and its variants may vary dramatically between cell types, tissues, and disease states .

• Non-specific binding: Secondary antibodies may create non-specific bands that could be misinterpreted as PL2L proteins, necessitating appropriate negative controls (e.g., no primary antibody controls) .

How can PIWIL2 antibodies be used to investigate cancer stem cell biology?

PIWIL2 antibodies offer valuable tools for investigating cancer stem cell (CSC) biology:

• CSC identification and isolation: Using PIWIL2 antibodies (particularly those recognizing PL2L proteins) to identify potential CSC populations in tumors and cell lines, as certain PL2L proteins like PL2L60 appear to be predominantly expressed in cancer cells .

• Functional studies: Combining PIWIL2 antibodies with markers of stemness to correlate PIWIL2/PL2L expression with stem cell properties.

• Expression pattern analysis: Comparing expression patterns between primary and metastatic tumors to understand the role of different PIWIL2 isoforms in cancer progression .

• Gene silencing studies: Using PIWIL2 antibodies to study the role of these proteins in RNA-mediated gene silencing mechanisms within CSCs, given PIWIL2's role in this process.

• Therapeutic targeting assessment: Evaluating the efficacy of PIWIL2-targeting therapies through antibody-based detection of remaining protein levels after treatment.

What are common pitfalls in PIWIL2 antibody experiments and how can they be avoided?

Common pitfalls and their solutions include:

• Misidentification of isoforms:

  • Pitfall: Attributing a band to full-length PIWIL2 when it's actually a PL2L protein.

  • Solution: Always use molecular weight markers and appropriate positive controls. Consider using antibodies with known specificity patterns like Kao1 (specific for full-length PIWIL2) alongside broader antibodies .

• Overlooking tissue-specific expression:

  • Pitfall: Failing to detect PIWIL2 due to using inappropriate positive controls.

  • Solution: Use testicular tissue as positive control for full-length PIWIL2 and cancer cell lines for PL2L60 .

• Non-specific binding:

  • Pitfall: Interpreting non-specific bands as PIWIL2 isoforms.

  • Solution: Include no-primary antibody controls and peptide competition assays to identify true specific binding .

• Incomplete blocking:

  • Pitfall: High background obscuring specific signals.

  • Solution: Optimize blocking conditions with 5% non-fat milk or BSA, and ensure adequate washing steps.

How should researchers interpret contradictory results across different PIWIL2 antibodies?

When facing contradictory results with different PIWIL2 antibodies:

• Compare epitope locations: Determine where each antibody binds on the PIWIL2 protein. Antibodies targeting different domains may give different results if certain domains are masked or absent in specific isoforms .

• Evaluate antibody specificity: Review specificity documentation for each antibody. Some antibodies (like Kao1) specifically recognize full-length PIWIL2, while others (like Kao2/Kao3) recognize both PIWIL2 and PL2L proteins .

• Consider isoform-specific expression: Different tissues and cell lines may predominantly express different isoforms. For example, tumor cell lines predominantly express PL2L60, while testicular tissue expresses more full-length PIWIL2 .

• Perform complementary techniques: Combine Western blot data with RT-PCR to determine which transcripts are present. GEM RT-PCR using primers covering different exon regions can help resolve which forms are expressed .

• Use knockout/knockdown models: Compare results with appropriate controls where PIWIL2 expression is reduced or eliminated, while being aware of potential limitations as seen in mili−/− mice where some PL2L variants remained detectable .

What quality control methods ensure reliable PIWIL2 antibody performance over time?

To ensure reliable PIWIL2 antibody performance:

• Antibody validation at receipt: Perform initial validation with positive controls (testicular tissue for full-length PIWIL2; cancer cell lines for PL2L60) and negative controls (peptide competition) .

• Aliquoting and storage: Store antibodies in small aliquots at -20°C or -80°C to minimize freeze-thaw cycles, which can degrade antibody quality.

• Routine performance checks: Include standard positive and negative controls in each experiment to monitor antibody performance over time.

• Lot-to-lot validation: When receiving a new lot, compare performance to previous lots using consistent positive controls.

• Documentation: Maintain detailed records of antibody performance, including optimal dilutions and exposure times for each application.

How are PIWIL2 antibodies being used to advance understanding of cancer biology?

PIWIL2 antibodies are advancing cancer biology research through:

• Cancer stem cell identification: Using antibodies recognizing PL2L proteins to identify and isolate potential cancer stem cells, as certain isoforms like PL2L60 appear predominantly expressed in these populations .

• Differential diagnosis: Investigating the expression patterns of PIWIL2 and its variants across different cancer types and stages to identify potential diagnostic biomarkers.

• Prognostic indicators: Correlating PIWIL2/PL2L expression levels with clinical outcomes to determine prognostic significance.

• Mechanistic studies: Exploring the functions of different PIWIL2 isoforms in cancer initiation, progression, and metastasis using isoform-specific antibodies .

• Therapeutic target validation: Using antibodies to confirm target engagement and efficacy of PIWIL2-directed therapeutics.

What recent developments have improved the specificity and applications of PIWIL2 antibodies?

Recent developments in PIWIL2 antibody technology include:

• Isoform-specific monoclonal antibodies: Development of antibodies like mAb Kao1 that specifically recognize full-length PIWIL2 without detecting PL2L proteins, enabling more precise analysis of isoform expression .

• Multi-epitope targeting strategies: Design of antibody panels targeting different regions of PIWIL2 to provide complementary information about isoform expression.

• Improved validation methods: Implementation of comprehensive validation approaches including peptide competition, knockout models, and cross-reactivity testing to ensure antibody specificity .

• Application-optimized formulations: Development of antibodies specifically validated for particular applications such as Western blot, immunohistochemistry, or flow cytometry .

What are the current limitations in PIWIL2 antibody research and potential future solutions?

Current limitations and potential solutions in PIWIL2 antibody research include:

• Incomplete isoform characterization:

  • Limitation: Not all PL2L proteins are fully characterized at the genetic level. For example, PL2L80 could not be predicted from NCBI GeneBank or Genomatix database .

  • Solution: Ongoing research to clone and characterize the full range of PL2L genes and proteins, as noted in research where PL2L80 cloning was in progress .

• Cross-reactivity challenges:

  • Limitation: Difficulty developing antibodies that specifically recognize each PL2L protein without cross-reactivity.

  • Solution: Epitope mapping to identify unique regions of each isoform, followed by targeted antibody development.

• Functional distinction:

  • Limitation: Difficulty attributing specific functions to individual PIWIL2 isoforms due to detection challenges.

  • Solution: Combining isoform-specific antibodies with functional assays and creating isoform-specific knockout models.

• Standardization:

  • Limitation: Variability in antibody performance across laboratories and applications.

  • Solution: Development of standardized protocols and reference materials for PIWIL2 antibody validation and use.